Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

31,147 trials

NCT07754123
Recruiting
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC
Phase 3 · China · 1 site
Registry update: 2 Nov 2026
NCT07775534
Recruiting
Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients
Not applicable · United States · 1 site
Registry update: 30 Oct 2026
NCT07882797
Recruiting
Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy
Not applicable · Germany · 1 site
Registry update: 27 Oct 2026
2026-526171-32-00
Recruiting
A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus
Phase 1 · Hungary, Poland · 7 sites
Registry update: 25 Sept 2026
NCT07829783
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Phase 3 · Taiwan, Ukraine · 10 sites
Registry update: 6 Nov 2026
NCT07836374
Recruiting
RENEW Intervention for Axial Spondyloarthritis
Not applicable · United States · 1 site
Registry update: 29 Oct 2026
NCT07822711
Recruiting
Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
Not applicable · China · 1 site
Registry update: 23 Oct 2026
NCT07806838
Recruiting
Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication
Not applicable · United States · 1 site
Registry update: 4 Nov 2026
NCT07876557
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
Phase 2 · China · 31 sites
Registry update: 5 Nov 2026
NCT07859722
Recruiting
CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
Not applicable · United States · 3 sites
Registry update: 2 Nov 2026
NCT07782359
Recruiting
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
Phase 1 · United States · 1 site
Registry update: 27 Oct 2026
NCT07912593
Recruiting
Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors
Phase 1/2 · United States · 1 site
Registry update: 3 Nov 2026
NCT07376018
Recruiting
Ketogenic Diet and Neuromodulation in Treatment Resistant Depression
Not applicable · Canada · 1 site
Registry update: 28 Oct 2026
NCT07885423
Recruiting
68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer
Not applicable · China · 1 site
Registry update: 6 Nov 2026
NCT07753850
Recruiting
A Study of SL-325 in Crohn's Disease Patients
Phase 2 · United States · 20 sites
Registry update: 3 Nov 2026
2025-524641-27-00
Recruiting
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
Phase 3 · Belgium, Germany, Spain, France, Ireland, Italy, Poland · 38 sites
Registry update: 30 Oct 2026
NCT07647432
Recruiting
HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
Phase 1 · United States · 1 site
Registry update: 26 Oct 2026
NCT07592546
Recruiting
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
Phase 4 · Canada · 1 site
Registry update: 26 Oct 2026
NCT07123779
Recruiting
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Phase 1/2 · United States · 3 sites
Registry update: 30 Oct 2026
NCT07883226
Recruiting
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
Phase 1 · South Africa · 1 site
Registry update: 22 Oct 2026

Ordered by registry start date. Freshness and sponsorship never change the order.